On October 25th, Carrie Lam, the Chief Executive of the Hong Kong Special Administrative Region, delivered the 2023 Policy Address to the Legislative Council, which highlighted a series of fertility incentives that garnered widespread attention from various sectors of society. These include the introduction of a new baby bonus, gradual increments in the allocation of assisted reproductive services for in vitro fertilization, and the reinforcement of training for related professional personnel.

In recent years, Hong Kong’s birth rate has consistently remained at a low level. Last year, the average number of children per couple decreased to a historic low of 0.9. Concurrently, the proportion of the elderly population in Hong Kong continues to rise, necessitating policy encouragement for childbirth.

In the Policy Address, Carrie Lam stated that the government will introduce a new baby bonus. Starting immediately, newborn babies born in Hong Kong to parents who are permanent residents will receive a one-time cash bonus of HK$20,000, valid for three years. The launch of this policy series signifies an important step taken by Hong Kong in incentivizing childbirth. By providing substantial policy incentives, the Hong Kong government is actively accelerating the establishment of a supportive policy system for childbirth and child-rearing, offering tangible incentives for childbirth. This move not only assists in improving Hong Kong’s fertility rate but also injects new vitality and impetus into Hong Kong’s future development. Experts note that Hong Kong’s market’s early implementation of substantive policies sets expectations for domestic policies within China.

About Golden Meditech

Golden Meditech, with decades of development, holds significant advantages in aspects such as success rates in in vitro fertilization (IVF), medical quality, patient experience, and operational management, accruing a strong reputation among patients. As a company centered on assisted reproductive services, Golden Meditech actively expands its range of products and services across the full cycle of fertility, dedicated to providing patients with the highest quality integrated fertility services and contributing to the country’s population health development.